Cargando…

Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network

This retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC) who received palbociclib plus an aromatase inhibitor as...

Descripción completa

Detalles Bibliográficos
Autores principales: Law, Jeanna Wallenta, Mitra, Debanjali, Kaplan, Henry G., Alfred, Tamuno, Brufsky, Adam M., Emir, Birol, McCracken, Haley, Liu, Xianchen, Broome, Ronda G., Zhang, Chenan, DiCristo, Caroline, Chen, Connie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871271/
https://www.ncbi.nlm.nih.gov/pubmed/35200588
http://dx.doi.org/10.3390/curroncol29020089
_version_ 1784656956974170112
author Law, Jeanna Wallenta
Mitra, Debanjali
Kaplan, Henry G.
Alfred, Tamuno
Brufsky, Adam M.
Emir, Birol
McCracken, Haley
Liu, Xianchen
Broome, Ronda G.
Zhang, Chenan
DiCristo, Caroline
Chen, Connie
author_facet Law, Jeanna Wallenta
Mitra, Debanjali
Kaplan, Henry G.
Alfred, Tamuno
Brufsky, Adam M.
Emir, Birol
McCracken, Haley
Liu, Xianchen
Broome, Ronda G.
Zhang, Chenan
DiCristo, Caroline
Chen, Connie
author_sort Law, Jeanna Wallenta
collection PubMed
description This retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC) who received palbociclib plus an aromatase inhibitor as first-line therapy in US community health systems. Using electronic health records from the Syapse Learning Health Network, 242 patients were identified as having received first-line palbociclib plus an aromatase inhibitor between 3 February 2015, and 31 July 2019 (data cutoff 1 February 2020) resulting in a minimum potential 6-month follow-up period. In total, 56.6% of patients had de novo A/MBC at initial breast cancer diagnosis, 50.8% had bone-only disease, and 32.2% had visceral disease. Median follow-up was 22.4 months. Disease progression (26.4%) and intolerance/toxicity (14.9%) were the main reasons for treatment discontinuation. The median (95% CI) real-world progression-free survival was 31.7 (27.9—not estimable (NE)) months and 2-year estimated overall survival (OS) rate was 78.0%. In total, 25.6% of patients died; however, OS data are limited by the small population size and insufficient follow-up time. These real-world effectiveness outcomes complement findings from other real-world studies and randomized controlled trials and support palbociclib plus an aromatase inhibitor as first-line therapy for HR+/HER2− A/MBC.
format Online
Article
Text
id pubmed-8871271
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88712712022-02-25 Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network Law, Jeanna Wallenta Mitra, Debanjali Kaplan, Henry G. Alfred, Tamuno Brufsky, Adam M. Emir, Birol McCracken, Haley Liu, Xianchen Broome, Ronda G. Zhang, Chenan DiCristo, Caroline Chen, Connie Curr Oncol Article This retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC) who received palbociclib plus an aromatase inhibitor as first-line therapy in US community health systems. Using electronic health records from the Syapse Learning Health Network, 242 patients were identified as having received first-line palbociclib plus an aromatase inhibitor between 3 February 2015, and 31 July 2019 (data cutoff 1 February 2020) resulting in a minimum potential 6-month follow-up period. In total, 56.6% of patients had de novo A/MBC at initial breast cancer diagnosis, 50.8% had bone-only disease, and 32.2% had visceral disease. Median follow-up was 22.4 months. Disease progression (26.4%) and intolerance/toxicity (14.9%) were the main reasons for treatment discontinuation. The median (95% CI) real-world progression-free survival was 31.7 (27.9—not estimable (NE)) months and 2-year estimated overall survival (OS) rate was 78.0%. In total, 25.6% of patients died; however, OS data are limited by the small population size and insufficient follow-up time. These real-world effectiveness outcomes complement findings from other real-world studies and randomized controlled trials and support palbociclib plus an aromatase inhibitor as first-line therapy for HR+/HER2− A/MBC. MDPI 2022-02-12 /pmc/articles/PMC8871271/ /pubmed/35200588 http://dx.doi.org/10.3390/curroncol29020089 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Law, Jeanna Wallenta
Mitra, Debanjali
Kaplan, Henry G.
Alfred, Tamuno
Brufsky, Adam M.
Emir, Birol
McCracken, Haley
Liu, Xianchen
Broome, Ronda G.
Zhang, Chenan
DiCristo, Caroline
Chen, Connie
Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
title Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
title_full Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
title_fullStr Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
title_full_unstemmed Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
title_short Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
title_sort real-world treatment patterns and clinical effectiveness of palbociclib plus an aromatase inhibitor as first-line therapy in advanced/metastatic breast cancer: analysis from the us syapse learning health network
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871271/
https://www.ncbi.nlm.nih.gov/pubmed/35200588
http://dx.doi.org/10.3390/curroncol29020089
work_keys_str_mv AT lawjeannawallenta realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork
AT mitradebanjali realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork
AT kaplanhenryg realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork
AT alfredtamuno realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork
AT brufskyadamm realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork
AT emirbirol realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork
AT mccrackenhaley realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork
AT liuxianchen realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork
AT broomerondag realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork
AT zhangchenan realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork
AT dicristocaroline realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork
AT chenconnie realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork